FAQ

Diana Ritchie

Suggest Changes
Robert E Coleman10
H. D. Sinnett10
B. Thürlimann8
Richard Bell8
Ingo J Diel8
18Robert E. Coleman
18Peyman Hadji
18Christina L. Addison
15Mark Clemons
14Bent Ejlertsen

Filter Results:

  • Full text PDF available (5)

Publication Year

1971
2018
  • This year (2)
  • Last 5 years (4)
  • Last 10 years (10)

Publication Type

Co-author

Journals and Conferences

Learn More
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer…
BACKGROUND Anthracyclines and taxanes have been the standard neoadjuvant chemotherapies for breast cancer in the past decade. We aimed to assess safety and efficacy of the addition of gemcitabine to… (More)
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
PURPOSE Denosumab was shown to be superior to zoledronic acid in preventing skeletal related events (SRE) in patients with breast cancer and bone metastases in a randomized, double-blind phase III… (More)
Five-year follow-up of participants in a randomised controlled trial showing benefits from exercise for breast cancer survivors during adjuvant treatment. Are there lasting effects?
PURPOSE In an earlier randomised controlled trial, we showed that early stage breast cancer patients who received a supervised exercise programme, with discussion of behaviour change techniques, had… (More)